Cargando…

Targeting Inflammation Driven by HMGB1

High mobility group box 1 (HMGB1) is a highly conserved, nuclear protein present in all cell types. It is a multi-facet protein exerting functions both inside and outside of cells. Extracellular HMGB1 has been extensively studied for its prototypical alarmin functions activating innate immunity, aft...

Descripción completa

Detalles Bibliográficos
Autores principales: Yang, Huan, Wang, Haichao, Andersson, Ulf
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7099994/
https://www.ncbi.nlm.nih.gov/pubmed/32265930
http://dx.doi.org/10.3389/fimmu.2020.00484
_version_ 1783511398536445952
author Yang, Huan
Wang, Haichao
Andersson, Ulf
author_facet Yang, Huan
Wang, Haichao
Andersson, Ulf
author_sort Yang, Huan
collection PubMed
description High mobility group box 1 (HMGB1) is a highly conserved, nuclear protein present in all cell types. It is a multi-facet protein exerting functions both inside and outside of cells. Extracellular HMGB1 has been extensively studied for its prototypical alarmin functions activating innate immunity, after being actively released from cells or passively released upon cell death. TLR4 and RAGE operate as the main HMGB1 receptors. Disulfide HMGB1 activates the TLR4 complex by binding to MD-2. The binding site is separate from that of LPS and it is now feasible to specifically interrupt HMGB1/TLR4 activation without compromising protective LPS/TLR4-dependent functions. Another important therapeutic strategy is established on the administration of HMGB1 antagonists precluding RAGE-mediated endocytosis of HMGB1 and HMGB1-bound molecules capable of activating intracellular cognate receptors. Here we summarize the role of HMGB1 in inflammation, with a focus on recent findings on its mission as a damage-associated molecular pattern molecule and as a therapeutic target in inflammatory diseases. Recently generated HMGB1-specific inhibitors for treatment of inflammatory conditions are discussed.
format Online
Article
Text
id pubmed-7099994
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-70999942020-04-07 Targeting Inflammation Driven by HMGB1 Yang, Huan Wang, Haichao Andersson, Ulf Front Immunol Immunology High mobility group box 1 (HMGB1) is a highly conserved, nuclear protein present in all cell types. It is a multi-facet protein exerting functions both inside and outside of cells. Extracellular HMGB1 has been extensively studied for its prototypical alarmin functions activating innate immunity, after being actively released from cells or passively released upon cell death. TLR4 and RAGE operate as the main HMGB1 receptors. Disulfide HMGB1 activates the TLR4 complex by binding to MD-2. The binding site is separate from that of LPS and it is now feasible to specifically interrupt HMGB1/TLR4 activation without compromising protective LPS/TLR4-dependent functions. Another important therapeutic strategy is established on the administration of HMGB1 antagonists precluding RAGE-mediated endocytosis of HMGB1 and HMGB1-bound molecules capable of activating intracellular cognate receptors. Here we summarize the role of HMGB1 in inflammation, with a focus on recent findings on its mission as a damage-associated molecular pattern molecule and as a therapeutic target in inflammatory diseases. Recently generated HMGB1-specific inhibitors for treatment of inflammatory conditions are discussed. Frontiers Media S.A. 2020-03-20 /pmc/articles/PMC7099994/ /pubmed/32265930 http://dx.doi.org/10.3389/fimmu.2020.00484 Text en Copyright © 2020 Yang, Wang and Andersson. http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Immunology
Yang, Huan
Wang, Haichao
Andersson, Ulf
Targeting Inflammation Driven by HMGB1
title Targeting Inflammation Driven by HMGB1
title_full Targeting Inflammation Driven by HMGB1
title_fullStr Targeting Inflammation Driven by HMGB1
title_full_unstemmed Targeting Inflammation Driven by HMGB1
title_short Targeting Inflammation Driven by HMGB1
title_sort targeting inflammation driven by hmgb1
topic Immunology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7099994/
https://www.ncbi.nlm.nih.gov/pubmed/32265930
http://dx.doi.org/10.3389/fimmu.2020.00484
work_keys_str_mv AT yanghuan targetinginflammationdrivenbyhmgb1
AT wanghaichao targetinginflammationdrivenbyhmgb1
AT anderssonulf targetinginflammationdrivenbyhmgb1